Proteases can be engineered into allosteric switches that transition from E* to E on demand63,64, as demonstrated by mutants of clotting factor Xa that bypass the intrinsic pathway of coagulation and ameliorate hemophilia conditions65, or mutants of thrombin23–26 that are effective in the treatment of thrombotic complications and stroke. The gene discussed is F10; the disease is hemophilia.